Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT01917552 | Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS | unknown | Phase 3 | 870 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 |
| clinicaltrials |
| NCT05627752 | Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | unknown | Phase 2 / Phase 3 | 120 | Zhongnan HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | unknown | Phase 3 | 360 | Nanjing Yoko Biomedical Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05893810 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | unknown | Phase 3 | 176 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04842071 | 18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment | unknown | Phase 3 | 2,500 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma(BELIEVE-01) | unknown | Phase 3 | 150 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02556762 | Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer(SUMC-EC-002) | unknown | Phase 3 | 202 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05189028 | Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer | unknown | Phase 3 | 290 | Chuangzhen ChenOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT00565708 | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers(ASCOLT) | unknown | Phase 3 | 1,587 | National Cancer Centre, SingaporeOTHER | 10 | Feb 2, 2024 | clinicaltrials |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | unknown | Phase 2 / Phase 3 | 1,194 | Alliance for Clinical Trials in OncologyOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01864096 | The Metformin Active Surveillance Trial (MAST) Study(MAST) | unknown | Phase 3 | 408 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05737563 | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC(Escape) | unknown | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06211023 | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer | unknown | Phase 2 / Phase 3 | 520 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 0 | Jan 18, 2024 | clinicaltrials |
| NCT02465736 | Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308) | unknown | Phase 3 | 610 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05954442 | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype(BCTOP-T-M03) | unknown | Phase 3 | 203 | Fudan UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT00957086 | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer | unknown | Phase 3 | 710 | National Cancer Centre, SingaporeOTHER | 13 | Jan 9, 2024 | clinicaltrials |
| NCT06150144 | The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma | unknown | Phase 3 | 40 | University of AleppoOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186986 | CD30 Imaging in Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 20 | University Medical Center GroningenOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT04338191 | mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer(FANTASTIC) | unknown | Phase 3 | 638 | Sun Yat-sen UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03256981 | Stereotactic Body Radiotherapy for the Treatment of OPD(HALT) | unknown | Phase 2 / Phase 3 | 113 | Institute of Cancer Research, United KingdomOTHER | 5 | Dec 26, 2023 | clinicaltrials |
| NCT05631041 | Effect of Silymarin in Metastatic Colorectal Cancer Patients | unknown | Phase 3 | 64 | Tanta UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04714190 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | unknown | Phase 3 | 351 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT00415233 | High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer(HiLo) | unknown | Phase 3 | 438 | University College, LondonOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | unknown | Phase 3 | 194 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05446324 | Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer(SENGA) | unknown | Phase 3 | 10 | UMC UtrechtOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05523609 | Vitamin D and Calcium Supplementation in Breast Cancer | unknown | Phase 2 / Phase 3 | 40 | Tanta UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06152471 | Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer(ASF-BC) | unknown | Phase 3 | 100 | Henrik LindmanOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04632758 | Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 3 | 292 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03926091 | Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer(CLOVER) | unknown | Phase 3 | 2,172 | Fudan UniversityOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval(MITO-8) | unknown | Phase 3 | 215 | National Cancer Institute, NaplesOTHER | 3 | Nov 13, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT05673590 | Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 612 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05673629 | Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer | unknown | Phase 3 | 552 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06116734 | Lapelga vs Gastrofil | unknown | Phase 3 | 74 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Nov 3, 2023 | clinicaltrials |
| NCT06110663 | A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy | unknown | Phase 3 | 314 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 1, 2023 | clinicaltrials |
| NCT04596800 | Prehabilitation Plus ERAS Versus ERAS in Gynecologic Oncology: a Randomized Clinical Trial(PROPER) | unknown | Phase 3 | 194 | Instituto Brasileiro de Controle do CancerOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06103279 | Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin | unknown | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 0 | Oct 26, 2023 | clinicaltrials |
| NCT05144867 | Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis(SRSvsWBRT) | unknown | Phase 3 | 98 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT00411138 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer(PORTEC-3) | unknown | Phase 3 | 670 | Leiden UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04219332 | Randomized Controlled Trial on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection | unknown | Phase 3 | 266 | Fujian Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 29, 2024source: clinicaltrials